Peripheral Neuropathy Complications from ABVD Chemotherapy
Vinblastine is the primary neurotoxic agent in ABVD, causing peripheral neuropathy in a dose-dependent manner, predominantly affecting sensory nerves with small fiber involvement that manifests as burning pain, paresthesias, and autonomic dysfunction. 1, 2
Primary Neurotoxic Agent and Mechanism
Vinblastine (the "V" in ABVD) is a vinca alkaloid that causes small fiber neuropathy through disruption of microtubule function in peripheral nerves. 1 The drug affects nerve terminals involved in temperature and pain perception, leading to:
- Sensory neuronopathy (ganglionopathy) due to damage of dorsal root ganglion cell bodies, which lack adequate blood-brain barrier protection and are therefore vulnerable to irreversible neurotoxic damage 1
- Length-dependent axonal neuropathy affecting distal nerves first in a "dying back" pattern 1
Clinical Manifestations
Sensory Symptoms (Most Common)
"Plus" symptoms:
- Burning sensation in feet and hands (hallmark of small fiber neuropathy) 1
- Acral pain and paresthesias (tingling, "pins and needles") 1
- Lancinating pain potentiated by pin-prick testing 1
- Dysesthesia, allodynia, and hyperalgesia 1
"Minus" symptoms:
- Numbness in glove-and-stocking distribution 1
- Impaired light touch, vibration sense, and proprioception 1
- Decreased pain and temperature sensation in affected areas 1
Motor Involvement (Less Common)
- Numbness of digits (most frequent motor manifestation) 2
- Loss of deep tendon reflexes 2
- Distal weakness and atrophy of small foot muscles 1
- Peripheral neuritis 2
- Tremor and cramps 1
Autonomic Dysfunction
Vinblastine-induced small fiber damage causes autonomic involvement including: 1
- Constipation (most common)
- Abdominal pain
- Postural hypotension
- Bladder disturbances
- Delayed gastric emptying
- Reduced heart rate variability
Rare Neurological Complications
- Mental depression 2
- Headache 2
- Convulsions 2
- Vestibular and auditory damage (eighth cranial nerve): partial or total deafness (temporary or permanent), dizziness, nystagmus, vertigo 2
Doxorubicin Contribution
While vinblastine is the primary culprit, doxorubicin (Adriamycin) can cause peripheral sensory and motor neuropathy, though this is less common than its cardiac toxicity. 3 The combination may have additive neurotoxic effects.
Critical Clinical Pitfalls
Drug Interaction Warning
Severe, excessive neurotoxicity occurs when ABVD is combined with ritonavir-boosted protease inhibitors (used in HIV treatment). 4 Ritonavir inhibits CYP3A4, which metabolizes vinblastine, leading to dramatically increased vinblastine concentrations and severe neuropathy. This is particularly relevant as Hodgkin lymphoma is the second most common non-AIDS-defining malignancy in HIV-positive patients. 4
Timing and Progression
- Symptoms typically occur within the first 2 months of treatment 1
- Progress during active treatment 1
- Usually stabilize after treatment completion 1
- Neurotoxicity may be irreversible, particularly with ganglionopathy 1
Assessment Requirements
Baseline and pre-cycle clinical evaluation is critical to detect neuropathy before it becomes irreversible. 1 Look specifically for:
- Distal sensory changes (light touch, vibration, pin-prick, temperature)
- Deep tendon reflexes
- Motor strength in distal muscles
- Autonomic symptoms (constipation, orthostatic symptoms)
- Gait and balance abnormalities
Asymmetric Presentation
The clinical picture may be asymmetrical, particularly with ganglionopathy, and predominantly involves proprioception but does not exclude motor involvement. 1 This asymmetry should prompt consideration of pre-existing neurological conditions like Charcot-Marie-Tooth disease. 1
Management Implications
Early detection through ongoing assessment before every cycle enables intervention before neuropathy becomes irreversible. 1 Conventional nerve conduction studies often do not mirror patients' symptoms and show only modest improvement despite clinical recovery, so clinical assessment takes precedence over electrophysiology. 1
Neurophysiology should be considered when:
- Asymmetric symptom pattern exists 1
- Normal clinical examination despite patient complaints 1
- Severe neurotoxicity with motor involvement occurs (to rule out predisposing conditions) 1
Note: Small fiber neuropathy may present with normal conventional neurophysiology. 1